FINANCINGS
Access Pharmaceuticals Inc. is seeking to raise up to $23 million in an underwritten public offering.
Advanced Cell Technology Inc. entered a $30 million stock purchase agreement with Lincoln Park Capital Fund LLC.
Auspex Pharmaceuticals Inc. filed to raise up to $87 million in an underwritten public offering.
Bluebird Bio Inc. sold 3 million shares at $34 each in a public offering for net proceeds of about $95.6 million.
Genocea Biosciences Inc. filed to raise $69 million through an underwritten public offering.
Globeimmune Inc. closed its IPO for gross proceeds of about $17.2 million.
Ocera Therapeutics Inc. priced an underwritten public offering for gross proceeds of $25.2 million.
Pfenex Inc. set terms for its IPO, seeking to raise $65 million from 5 million shares in the range of $12 to $14.
Resverlogix Corp. amended its loan agreement with Citibank NA increasing it by $30 million for a total of $68.8 million.
Sage Therapeutics Inc. set terms for its IPO, seeking to raise up to $76.3 million.
Viking Therapeutics Inc. filed to raise up to $57.5 million, including overallotments, in an IPO.
DEALS
Abbvie Inc. improved its offer for Shire plc, which now values the potential transaction at $51.3 billion.
Astrazeneca plc and technology transfer organization MRC Technology renewed their strategic collaboration.
Baxter International Inc. acquired Aesrx LLC, gaining rights to Aes-103 indicated for sickle cell disease.
Dermira Inc. and UCB SA inked a deal for the development of Cimzia (certolizumab pegol) in dermatology.
Mariel Therapeutics Inc. is acquiring Stryker Corp.'s Bone Morphogenetic Protein-7 assets.
Xellia Pharmaceuticals AS acquired a lyophilized vial manufacturing facility in Raleigh, N.C., from Fresenius Kabi AG.
Yabao Pharmaceutical Co. Inc. partnered with Eli Lilly and Co. to co-develop Lilly's glucokinase activator (GKA), LY2608204.
. . . AND MORE
Anacor Pharmaceuticals Inc. received FDA approval for Kerydin (tavaborole) for onychomycosis.
Myos Corp. received approval to list on Nasdaq under existing ticker symbol MYOS.
Nippon Kayaku Co. Ltd. obtained marketing approval of an infliximab biosimilar jointly developed with Celltrion Inc.
Salix Pharmaceuticals Ltd. is combining with an Irish subsidiary of Cosmo Pharmaceuticals SpA in an all-stock transaction valued at about $2.6 billion.
Spectrum Pharmaceuticals Inc. received FDA conditional approval for its peripheral T-cell lymphoma (PTCL) therapy, Beleodaq (belinostat).
Summit Corp. gained FDA qualified infectious disease product designation for drug candidate SMT19969 for the treatment of C. difficile infection.
The EMA put out a consultation paper on the Advanced Therapy Medicinal Products regulation, which is up for review.
The Innovative Medicines Initiative 2 launched the first two calls in which $66.8 million is available for research in type 1 diabetes and retinal diseases.
The UK is launching a competition for teaching hospitals to set up specialist Genomic Medicines Centers as part of the 100,000 Genomes Project.